CGRP, the calcitonin gene-related peptide, inhibits excessive osteoclast activity while promoting osteoblast function, supporting a remodeling process that favors net bone formation
keep containers closed when not in use
Mounjaro is approved for use in adults with a BMI of 30kg/m or more (obesity), as well as those with a BMI of 27 to 30kg/m, who also have other weight-related health problems
doi: 10.3389/fphar.2024.1412245 Received 04 April 2024 Accepted 24 June 2024 Published 18 July 2024 Volume 15 - 2024 Edited by Irina Ielciu, University of Medicine and Pharmacy Iuliu Hatieganu, Romania Reviewed by Javad Mottaghipisheh, Swedish University of Agricultural Sciences, Sweden Shaymaa Mahmoud, University of Menoufia, Egypt Ufuk Koca alilkan, Gazi University, Trkiye Aida Abd El-Wahed, Agricultural Research Center, Egypt Gandhi Radis Baptista, Federal University of Ceara, Brazil Updates Copyright 2024 Sadek, Shib, Taher, Rashed, Shukry, Atia, Taymour, El-Nablaway, Ibrahim, Ramadan, Abdelkader, Abdo, Imbrea, Pet, Ali and Abdeen